Stock Financial Ratios, Dividends, Split History

PRA / ProAssurance Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,162.34
Enterprise Value ($M)2,439.65
Book Value ($M)1,594.80
Book Value / Share29.83
Price / Book1.34
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 53,457,000
Common Shares Outstanding 53,457,021
Weighted Average Number Of Shares Outstanding Basic 53,393,000
Weighted Average Number Of Diluted Shares Outstanding 53,611,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.02
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Supplementary Insurance Information Premium Revenue738,531,000.00
Net Income107.26
Earnings Per Share Diluted2.00
Earnings Per Share Basic2.01
Cash Flow Statement (mra) ($M)
Cash From Operations149.00
Cash from Investing224.67
Cash from Financing224.67
Identifiers and Descriptors
Central Index Key (CIK)1127703

Split History

Stock splits are used by ProAssurance Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

ProAssurance Hits 52-Week Low & Shares Fall 24%, Here's Why

2018-05-18 zacks
On May 17, shares of ProAssurance Corporation (PRA - Free Report) hit 52-week low of $39.65. The stock seems to have fallen out of favor with investors, following disappointing first-quarter results. (2-0)

ProAssurance's (PRA) CEO Stan Starnes on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Good morning, everyone. Welcome to the Conference Call to discuss ProAssurance's Results for the First Quarter 2018. (1-0)

ProAssurance (PRA) Q1 Earnings Miss Estimates, Down Y/Y

2018-05-04 zacks
ProAssurance Corporation’s (PRA - Free Report) first-quarter 2018 operating earnings per share of 40 cents missed the Zacks Consensus Estimate by 6.9%. Also, the bottom line declined 35.5% year over year. (20-0)

Avoid ProAssurance (PRA), Check These Top 3 Insurers Instead

2018-03-27 zacks
ProAssurance Corporation (PRA - Free Report) has been recently witnessing downward revisions. The stock has seen the Zacks Consensus Estimate for 2018 earnings being revised 11% downward. For 2019, our consensus estimate has moved 1.6% south. (15-0)

Why Is ProAssurance (PRA) Down 3.2% Since its Last Earnings Report?

2018-03-23 zacks
A month has gone by since the last earnings report for ProAssurance Corporation (PRA - Free Report) . Shares have lost about 3.2% in that time frame. (3-0)

CUSIP: 74267C106